2nd Sep 2019 08:48
(Alliance News) - AstraZeneca PLC on Monday reported positive study results for two separate treatments for prevention of cardiovascular events, particularly heart attacks in patients with or without type-2 diabetes.
London listed shares of the pharmaceutical company were up 1.3% at 7,414.00 pence each in morning trade.
Astra said Phase III THEMIS trial showed Brilinta, or ticagrelor, plus aspirin reduced the relative risk of cardiovascular death, heart attack, or stroke by 10% compared with aspirin alone in patients with coronary artery disease and type-2 diabetes.
The study also showed 15% relative risk reduction for cardiovascular events with patients who had previously undergone a percutaneous coronary intervention, a procedure to open a blocked or narrowed coronary artery.
AstraZeneca intends to work with regulatory authorities to explore an update to the Brilinta label based on the test results.
Separately, the company detailed results from the Phase III DAPA-HF trial showed Farxiga, or dapagliflozin, on top of standard of care reduced both the incidence of cardiovascular death and the worsening of heart failure in patients with reduced ejection fraction, with and without Type-2 diabetes.
Astra, in August, reported topline results for DAPA-HF trial which met the primary endpoint. Farxiga is currently approved to treat patients with Type-2 diabetes.
Farxiga study results showed a 30% decrease in the risk of experiencing a first episode of worsening heart failure and an 18% decrease in the risk of dying from cardiovascular causes, Astra noted.
Related Shares:
Astrazeneca